Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

I-Mab

IMAB
Current price
1.84 USD -0.02 USD (-1.08%)
Last closed 1.86 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 150 442 192 USD
Yield for 12 month -39.87 %
1Y
3Y
5Y
10Y
15Y
IMAB
21.11.2021 - 28.11.2021

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland. Address: New Bund Center, Shanghai, China, 200124

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

26 USD

P/E ratio

Dividend Yield

Current Year

+3 818 918 USD

Last Year

-30 608 120 USD

Current Quarter

+152 484 USD

Last Quarter

+391 753 USD

Current Year

+3 818 918 USD

Last Year

-34 370 812 USD

Current Quarter

+152 484 USD

Last Quarter

+391 753 USD

Key Figures IMAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -1 212 070 016 USD
Operating Margin TTM -7062.8 %
PE Ratio
Return On Assets TTM -23.11 %
PEG Ratio
Return On Equity TTM -63.34 %
Wall Street Target Price 26 USD
Revenue TTM 27 644 000 USD
Book Value 21.29 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -62.1 %
Dividend Yield
Gross Profit TTM 41 594 000 USD
Earnings per share -2.48 USD
Diluted Eps TTM -2.48 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics IMAB

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History IMAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation IMAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.9873
Price Sales TTM 5.284
Enterprise Value EBITDA 0.1122
Price Book MRQ 0.4306

Financials IMAB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators IMAB

For 52 weeks

1.16 USD 3.26 USD
50 Day MA 1.79 USD
Shares Short Prior Month 1 179 259
200 Day MA 1.68 USD
Short Ratio 6.79
Shares Short 1 225 458
Short Percent 3.61 %

Dynamics of changes in the value of assets

Stocks


AAPL

AAPL

212.49 USD Apple Inc -1.32 (-0.62%)
Detailed analytics

ETF funds


S

SX7EEX

13.36 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) -0.53 (-3.54%)
Detailed analytics

Metals


Gold

2332.52 USD Gold +27.54 (+1.2%)
Detailed analytics